Cargando…

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease

Detalles Bibliográficos
Autores principales:	Stoker, Thomas B., Andresen, Katie E.R., Barker, Roger A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894279/ https://www.ncbi.nlm.nih.gov/pubmed/33125799 http://dx.doi.org/10.1002/mds.28359

Ejemplares similares

Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
por: Rook, Morgan E., et al.
Publicado: (2022)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides
por: Linninger, Andreas A., et al.
Publicado: (2023)

Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs
por: Gagnon, Keith T., et al.
Publicado: (2019)

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017)

Hypertension, Antihypertensive Use and the Delayed‐Onset of Huntington's Disease
por: Steventon, Jessica J., et al.
Publicado: (2020)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
por: Kavallaris, M, et al.
Publicado: (1999)

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
por: McPhillips, F, et al.
Publicado: (2001)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system
por: Sullivan, Jenna M., et al.
Publicado: (2020)

Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
por: Langbehn, Douglas R., et al.
Publicado: (2020)

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
por: Niemela, Valter, et al.
Publicado: (2020)

A Critical Review of White Matter Changes in Huntington’s Disease
por: Casella, Chiara, et al.
Publicado: (2020)

Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review
por: Bakels, Hannah S., et al.
Publicado: (2021)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

Antisense oligonucleotide therapy for KCNT1 encephalopathy
por: Burbano, Lisseth Estefania, et al.
Publicado: (2022)

Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease
por: Morris, Lee‐Anne, et al.
Publicado: (2022)

Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022)

Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
por: Langbehn, Douglas R., et al.
Publicado: (2022)

Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021)

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
por: Martinovich, Kelly M., et al.
Publicado: (2018)

Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases
por: Verma, Ashok
Publicado: (2018)

Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model
por: Koch, Ellen T., et al.
Publicado: (2022)

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
por: Scoles, Daniel R., et al.
Publicado: (2017)

A Prion in yeast Huntington's disease
por: Dove, Alan W.
Publicado: (2002)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
por: Kim, Young Jin, et al.
Publicado: (2022)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy‐like Phenotype
por: Dewan, Ramita, et al.
Publicado: (2022)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
por: Giudice, Valentina, et al.
Publicado: (2020)

Antisense oligonucleotide is a promising intervention for liver diseases
por: Lu, Kailing, et al.
Publicado: (2022)

Fetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction
por: Wang, Lingyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4rpm5v5lrbsg6smq1smli0u259